J.Safra Asset Management Corp Acquires New Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• J.Safra Asset Management Corp acquired a new position in Teva Pharmaceutical Industries, purchasing 15,552 shares valued at approximately $261,000 during the second quarter.
• Wall Street analysts have issued a buy consensus rating on Teva, with target prices raised from $23 to $26 by both JPMorgan and UBS Group.
• Insider Placid Jover sold 6,053 shares at an average price of $15.16, reflecting a 47.19% decrease in their position, highlighting potential shifts in insider confidence.

J.Safra Asset Management Corp bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,552 shares of the company's stock, valued at approximately $261,000.

Other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth $43,000. Sound Income Strategies LLC grew its stake in Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after buying an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $74,000. Finally, CWM LLC grew its position in shares of Teva Pharmaceutical Industries by 18.1% during the second quarter. CWM LLC now owns 4,995 shares of the company's stock worth $84,000 after acquiring an additional 767 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent research reports. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.57.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $20.02 on Tuesday. The stock has a fifty day moving average price of $18.60 and a two-hundred day moving average price of $17.00. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm has a market cap of $22.96 billion, a P/E ratio of -125.09, a PEG ratio of 1.10 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same period last year, the company posted $0.61 EPS. The firm's quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.